Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early hydroxychloroquine macular toxicity.

A E Warner

    Arthritis and Rheumatism
    |August 18, 2001
    PubMed
    Summary
    This summary is machine-generated.

    Hydroxychloroquine (HCQ) maculopathy can occur in patients with systemic lupus erythematosus even at appropriate doses. Early screening is crucial for detecting this vision-threatening condition.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Activity of pulmonary intravascular macrophages in cats and dogs with and without adult Dirofilaria immitis.

    Veterinary parasitology·2008
    Same author

    Stage-specific and differential expression of gap junctions in the mouse ovary: connexin-specific roles in follicular regulation.

    Reproduction (Cambridge, England)·2001
    Same author

    Primary neuronal differentiation in Xenopus embryos is linked to the beta(3) subunit of the sodium pump.

    Developmental biology·2001
    Same author

    Effects of a perfluorochemical emulsion on the fate of circulating Pseudomonas aeruginosa.

    The American journal of physiology·1999
    Same author

    The neurotransmitter noradrenaline drives noggin-expressing ectoderm cells to activate N-tubulin and become neurons.

    Developmental biology·1999
    Same author

    Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species.

    The American journal of physiology·1999
    Same journal

    Proceedings of the Annual Meeting of the American Rheumatism Association.

    Arthritis and rheumatism·2020
    Same journal

    The regional distribution of rheumatologists: what can we do, what should we do?

    Arthritis and rheumatism·2013
    Same journal

    Regional distribution of adult rheumatologists.

    Arthritis and rheumatism·2013
    Same journal

    Clinically significant renal involvement in primary Sjögren's syndrome: clinical presentation and outcome.

    Arthritis and rheumatism·2013
    Same journal

    Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study.

    Arthritis and rheumatism·2013
    Same journal

    Association of low baseline levels of erythrocyte folate with treatment nonresponse at three months in rheumatoid arthritis patients receiving methotrexate.

    Arthritis and rheumatism·2013
    See all related articles

    Area of Science:

    • Ophthalmology
    • Rheumatology
    • Pharmacology

    Background:

    • Hydroxychloroquine (HCQ) is a widely used medication for autoimmune conditions like systemic lupus erythematosus (SLE).
    • Long-term HCQ use is associated with a risk of retinal toxicity, known as HCQ-associated maculopathy.
    • Understanding the risk factors and early detection methods is critical for patient safety.

    Observation:

    • A case report details a patient with SLE who developed maculopathy.
    • The patient received appropriate dosing of hydroxychloroquine.
    • Maculopathy manifested less than 8 years after initiating HCQ therapy.

    Findings:

    • HCQ-associated maculopathy can occur even with correct dosing and within a relatively short timeframe.
    • This case highlights the potential for ocular toxicity despite adherence to treatment guidelines.

    Related Experiment Videos

  • Individual patient susceptibility to HCQ toxicity may vary.

    • Implications:

    • Reinforces the importance of regular ophthalmological screening for all patients on long-term HCQ therapy, regardless of dose.
    • Suggests that current screening protocols may need re-evaluation for earlier detection of HCQ maculopathy.
    • Emphasizes the need for continued research into risk factors and predictive markers for HCQ retinopathy.